Delivery Order SPE2DB22D6029-SPE2DB25FLWAC
- Not listed
- The Defense Logistics Agency awarded a $1,599.24 delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) under a firm fixed-price contract, with an ultimate completion date of June 17, 2025. This non-set-aside award was competitively procured and represents a single delivery order fulfilling federal pharmaceutical supply requirements. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a...
- The Defense Logistics Agency awarded a delivery order valued at $8,137.72 to AmerisourceBergen Drug Corp for XELJANZ XR 11 MG tablets (30-count units) on August 4, 2025, with completion scheduled for August 5, 2025. This firm fixed-price delivery order represents a non-set-aside competitive procurement supporting federal pharmaceutical supply needs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for...
- The Defense Logistics Agency awarded a $6,239.99 firm fixed-price delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 MG tablets (30-count unit of use packaging). The contract was awarded on August 29, 2025, with an ultimate completion date of September 2, 2025, and represents a non-set-aside, competitively awarded procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal...
- The Defense Logistics Agency awarded a $9,139.66 firm fixed-price delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units), with an ultimate completion date of September 23, 2025. This non-set-aside, competitively awarded contract represents a single delivery order under AmerisourceBergen's broader relationship with DLA for pharmaceutical supply. The vendor, headquartered in Conshohocken, Pennsylvania, serves as a major pharmaceutical distributor supporting...
- The Defense Logistics Agency awarded a delivery order valued at $13,322.71 to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) on August 6, 2025, with completion expected by August 7, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a continuation of AmerisourceBergen's pharmaceutical supply relationship with DLA. The product will be delivered to AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of XELJANZ XR 11 mg tablets in a quantity of 30 units, valued at $8,055.93. This is a firm fixed price delivery order with no set-aside designation, indicating the award was made through open competition. The order is scheduled for completion by September 16, 2025, and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania location. This delivery order is issued...
- The Defense Logistics Agency awarded a $34.7K firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for supply of XELJANZ XR 11 mg tablets in quantities of 30 count units. The contract, which is not set-aside and carries an ultimate completion date of July 23, 2025, represents a single delivery order executed under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a delivery order valued at $6,671.56 to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) under a firm fixed-price contract. The award was made on June 3, 2025, with an ultimate completion date of June 4, 2025, and represents a non-set-aside competitive procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical...
- The Defense Logistics Agency awarded a $28,849.31 firm fixed-price delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 MG tablets (30-count units) with an ultimate completion date of June 20, 2025. This non-set-aside competitive award represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The pharmaceutical distributor, headquartered in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $9,926.00 to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) on August 7, 2025, with an ultimate completion date of August 8, 2025. This firm fixed-price delivery order is not set-aside and was competitively awarded. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement, particularly supporting...
- SPE2DB22D6029Indefinite Delivery Contract
- SPE2DB22D6029-SPE2DB25FLWACDelivery Order
The Defense Logistics Agency awarded a $6,199.32 delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) on September 17, 2025, with completion scheduled for September 18, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement needs across military and veteran healthcare systems. This delivery order represents a single transaction under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The comprehensive IDC enables the company to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs globally. XELJANZ XR is a specialty pharmaceutical used in the treatment of certain inflammatory and autoimmune conditions, reflecting the broad therapeutic portfolio that AmerisourceBergen Drug Corp delivers to support the Defense Health Agency and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.2k | 9/17/25 |